Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 10 - 18 save search
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
ALKS | $23.78 -1.0% -1.01% 1.6M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -4.36%
treatment schizophrenia commercialization
BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
BTAI 4 | $2.69 -2.18% -2.23% 230K
|
Health Technology
|
| O: 0.15%
H: 6.75%
C: 3.39%
treatment phase 2 prostate cancer expansion endocrine cancer trial merge
Adamis Receives FDA Approval for ZIMHINew High-Dose Naloxone Product for the Treatment of Opioid Overdose
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 23.01%
H: 6.47%
C: -11.51%
treatment fda opioid fda approval approval
Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI for the Treatment of Acute Hepatic Porphyria (AHP) in Adults
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -2.37%
treatment positive drug technology hepatitis
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
VRTX | $394.17 -0.8% -0.82% 690K
|
Health Technology
|
| O: 0.4%
H: 0.11%
C: -0.93%
diabetes treatment stem cell phase 1 positive therapy trial
Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
VVOS | $2.73 -1.44% -1.47% 75K
|
Health Technology
|
| O: 2.25%
H: 10.74%
C: 6.89%
treatment collaboration liver
Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2021-10-18 (Crawled : 17:00) - biospace.com/
RARE | $42.32 -1.28% -1.3% 890K
|
Health Technology
|
| O: -1.4%
H: 0.27%
C: -1.09%
disease treatment gene therapy therapy trial
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Published: 2021-10-18 (Crawled : 14:00) - biospace.com/
RNA | $23.91 0.0% 720K
|
Health Technology
|
| O: -0.28%
H: 3.54%
C: -4.94%
treatment fda fast track fast track designation granted grant designation
Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Published: 2021-10-18 (Crawled : 14:00) - biospace.com/
ATXS A | $11.1 1.93% 1.89% 460K
|
Manufacturing
|
| O: -0.43%
H: 1.14%
C: -7.14%
disease treatment ema rare hereditary angioedema
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2021-10-18 (Crawled : 13:00) - biospace.com/
MBRX | $4.355 -2.35% -2.41% 16K
|
Health Technology
|
| O: 3.32%
H: 0.0%
C: -4.29%
treatment phase 1 trial phase 1b soft tissue phase 2b
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
Published: 2021-10-18 (Crawled : 13:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -1.83%
H: 0.13%
C: -2.37%
food treatment drug hiv xin
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
Published: 2021-10-18 (Crawled : 12:00) - biospace.com/
OMER | $3.43 1.48% 1.46% 240K
|
Health Technology
|
| O: -21.64%
H: 0.49%
C: -7.35%
treatment fda application license response
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
Published: 2021-10-18 (Crawled : 11:00) - aslanpharma.com
ASLN | $0.491 -2.83% -2.91% 110K
|
Health Technology
|
| O: -1.86%
H: 4.43%
C: 0.63%
treatment dermatitis atopic dermatitis
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
Published: 2021-10-18 (Crawled : 10:00) - prnewswire.com
OYST | $11.17 0.18% -0.27%
|
Health Technology
|
| O: 9.77%
H: 2.68%
C: -7.29%
dry eye disease nasal spray treatment fda eye fda approval eye disease approval
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
Published: 2021-10-18 (Crawled : 01:00) - prnewswire.com
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
INCY | $53.23 -0.37% -0.38% 1.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -1.45%
treatment lung cancer cancer phase 3
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.